Compass Therapeutics Inc.
CMPX5.170USD
+0.030+0.58%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
918.05MMarket Cap
LossP/E TTM
More Details of Compass Therapeutics Inc. Company
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Compass Therapeutics Inc. Info
Ticker SymbolCMPX
Company nameCompass Therapeutics Inc.
IPO dateNov 13, 2020
CEOSchuetz (Thomas J)
Number of employees35
Security typeOrdinary Share
Fiscal year-endNov 13
Address80 Guest Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02135
Phone16175008099
Websitehttps://www.compasstherapeutics.com/
Ticker SymbolCMPX
IPO dateNov 13, 2020
CEOSchuetz (Thomas J)
Company Executives of Compass Therapeutics Inc.
Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan Anderman, J.D.
Mr. Jonathan Anderman, J.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
20.00K
--
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Independent Director
Independent Director
--
-100.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Thomas J. Schuetz, M.D., Ph.D.
Dr. Thomas J. Schuetz, M.D., Ph.D.
Chief Executive Officer, Vice Chairman of the Board
Chief Executive Officer, Vice Chairman of the Board
--
--
Mr. Barry Shin, J.D.
Mr. Barry Shin, J.D.
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. James P. (Jim) Boylan
Mr. James P. (Jim) Boylan
Independent Director
Independent Director
--
--
Ms. Ellen V. Chiniara, J.D.
Ms. Ellen V. Chiniara, J.D.
Independent Director
Independent Director
--
--
Mr. Philip J. (Phil) Ferneau, J.D.
Mr. Philip J. (Phil) Ferneau, J.D.
Independent Director
Independent Director
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Neil Lerner
Mr. Neil Lerner
Senior Vice President, Chief Accounting Officer and Principal Accounting Officer
Senior Vice President, Chief Accounting Officer and Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan Anderman, J.D.
Mr. Jonathan Anderman, J.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
20.00K
--
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Independent Director
Independent Director
--
-100.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Thomas J. Schuetz, M.D., Ph.D.
Dr. Thomas J. Schuetz, M.D., Ph.D.
Chief Executive Officer, Vice Chairman of the Board
Chief Executive Officer, Vice Chairman of the Board
--
--
Mr. Barry Shin, J.D.
Mr. Barry Shin, J.D.
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. James P. (Jim) Boylan
Mr. James P. (Jim) Boylan
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
9.45%
OrbiMed Advisors, LLC
8.56%
Suvretta Capital Management, LLC
7.93%
Vivo Capital, LLC
5.37%
Blackstone Alternative Asset Management, L.P.
5.08%
Other
63.62%
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
9.45%
OrbiMed Advisors, LLC
8.56%
Suvretta Capital Management, LLC
7.93%
Vivo Capital, LLC
5.37%
Blackstone Alternative Asset Management, L.P.
5.08%
Other
63.62%
Shareholder Types
Shareholders
Proportion
Hedge Fund
35.45%
Investment Advisor
15.39%
Investment Advisor/Hedge Fund
14.37%
Private Equity
9.01%
Venture Capital
8.07%
Individual Investor
6.62%
Corporation
4.38%
Research Firm
0.83%
Bank and Trust
0.13%
Other
5.74%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
216
147.60M
70.29%
+4.00M
2025Q3
229
143.60M
71.74%
+35.92M
2025Q2
213
103.56M
80.11%
+6.69M
2025Q1
220
104.04M
82.54%
-10.09M
2024Q4
203
96.62M
79.95%
+1.45M
2024Q3
186
95.17M
80.78%
-3.77M
2024Q2
180
95.63M
78.40%
-1.71M
2024Q1
175
97.35M
71.88%
-1.55M
2023Q4
171
88.59M
77.07%
-2.26M
2023Q3
160
90.10M
77.42%
-817.20K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tang Capital Management, LLC
13.50M
7.87%
+2.44M
+22.11%
Jun 30, 2025
OrbiMed Advisors, LLC
15.22M
8.87%
--
--
Aug 15, 2025
Suvretta Capital Management, LLC
14.10M
8.22%
+6.95M
+97.23%
Aug 13, 2025
Vivo Capital, LLC
6.04M
3.52%
+2.49M
+69.95%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
8.52M
4.97%
--
--
Jun 30, 2025
Enavate Sciences GP, LLC
7.79M
4.54%
--
--
Aug 14, 2025
The Vanguard Group, Inc.
4.85M
2.83%
+12.00K
+0.25%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.82M
3.39%
-680.88K
-10.47%
Jun 30, 2025
Schuetz (Thomas J.)
5.60M
3.27%
+10.00K
+0.18%
May 27, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ALPS Medical Breakthroughs ETF
0.27%
Vanguard US Momentum Factor ETF
0.07%
iShares Micro-Cap ETF
0.07%
State Street SPDR S&P Biotech ETF
0.06%
Direxion Daily S&P Biotech Bull 3X Shares
0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
View more
ALPS Medical Breakthroughs ETF
Proportion0.27%
Vanguard US Momentum Factor ETF
Proportion0.07%
iShares Micro-Cap ETF
Proportion0.07%
State Street SPDR S&P Biotech ETF
Proportion0.06%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.03%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Compass Therapeutics Inc.?
The top five shareholders of Compass Therapeutics Inc. are:
Tang Capital Management, LLC holds 13.50M shares, accounting for 7.87% of the total shares.
OrbiMed Advisors, LLC holds 15.22M shares, accounting for 8.87% of the total shares.
Suvretta Capital Management, LLC holds 14.10M shares, accounting for 8.22% of the total shares.
Vivo Capital, LLC holds 6.04M shares, accounting for 3.52% of the total shares.
Blackstone Alternative Asset Management, L.P. holds 8.52M shares, accounting for 4.97% of the total shares.
Tang Capital Management, LLC holds 13.50M shares, accounting for 7.87% of the total shares.
OrbiMed Advisors, LLC holds 15.22M shares, accounting for 8.87% of the total shares.
Suvretta Capital Management, LLC holds 14.10M shares, accounting for 8.22% of the total shares.
Vivo Capital, LLC holds 6.04M shares, accounting for 3.52% of the total shares.
Blackstone Alternative Asset Management, L.P. holds 8.52M shares, accounting for 4.97% of the total shares.
What are the top three shareholder types of Compass Therapeutics Inc.?
The top three shareholder types of Compass Therapeutics Inc. are:
Tang Capital Management, LLC
OrbiMed Advisors, LLC
Suvretta Capital Management, LLC
Tang Capital Management, LLC
OrbiMed Advisors, LLC
Suvretta Capital Management, LLC
How many institutions hold shares of Compass Therapeutics Inc. (CMPX)?
As of 2025Q4, 216 institutions hold shares of Compass Therapeutics Inc., with a combined market value of approximately 147.60M, accounting for 70.29% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.45%.
What is the biggest source of revenue for Compass Therapeutics Inc.?
In FY2025Q2, the -- business generated the highest revenue for Compass Therapeutics Inc., amounting to -- and accounting for --% of total revenue.
